Ocular Surface Optimization Before Surgery

Ocular surface optimization (OSO) before intraocular surgery — particularly cataract surgery with premium IOL implantation and corneal refractive surgery — has emerged as a standard of care over the past decade. The ocular surface is the foundation of all preoperative measurements: keratometry, corneal topography, and optical biometry all depend on a stable, regular tear film for accurate data acquisition. Unoptimized ocular surface disease (OSD) — dry eye, MGD, blepharitis, epithelial irregularity — introduces measurement variability that leads to IOL power calculation errors, refractive surprise, and patient dissatisfaction. The optometrist is ideally positioned to identify and treat OSD before surgical referral.

OSD is present in approximately 50–80% of cataract surgery candidates, with MGD being the most prevalent form. Studies have shown that preoperative OSD is associated with a 2–3× higher rate of refractive surprise after cataract surgery. Patient dissatisfaction after premium IOL implantation is disproportionately driven by unrecognized or undertreated OSD — particularly in multifocal and EDOF IOL recipients, who are more sensitive to optical aberrations from surface irregularity.

The tear film is the first refracting surface of the eye. An unstable or irregular tear film produces variable keratometric readings, irregular corneal topography, and inaccurate axial length measurements (particularly with optical biometry, which depends on a clear optical path). MGD — the most common cause of evaporative dry eye — produces lipid layer deficiency, tear film instability, and epithelial irregularity. Blepharitis introduces inflammatory mediators that destabilize the tear film and alter corneal curvature. These surface irregularities introduce systematic errors into IOL power calculations, leading to refractive surprise.

Patients may be asymptomatic or report classic dry eye symptoms (fluctuating vision, foreign body sensation, tearing). The critical finding is measurement variability: inconsistent keratometry readings between visits or between instruments, irregular corneal topography (asymmetric mires, irregular surface map), and variable axial length measurements. TBUT < 10 seconds, corneal staining, lid margin telangiectasia, meibomian gland dropout on meibography, and reduced Schirmer scores are objective markers of OSD.

A structured OSO protocol before surgical referral: (1) Treat MGD: warm compresses, lid hygiene, omega-3 supplementation, in-office thermal pulsation (LipiFlow, iLux) for moderate-to-severe MGD. (2) Treat aqueous deficiency: preservative-free artificial tears, punctal occlusion, cyclosporine 0.05–0.09% (Restasis, Cequa) or lifitegrast 5% (Xiidra). (3) Treat blepharitis: lid scrubs, hypochlorous acid (Avenova), azithromycin ophthalmic gel (AzaSite) for posterior blepharitis. (4) Treat Demodex: Xdemvy (lotilaner 0.25%) for confirmed Demodex blepharitis. (5) Repeat biometry after 4–8 weeks of treatment — confirm measurement reproducibility before finalizing IOL calculations. (6) Communicate OSD status to the surgeon — document the treatment course and residual surface findings.

Repeat keratometry and corneal topography after OSO treatment to confirm measurement stability. TBUT, corneal staining, and meibomian gland assessment at every preoperative visit. Postoperative monitoring for CME and surface-related refractive outcomes.